• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

换用长效注射用抗精神病药物治疗对精神分裂症患者的影响。

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia.

作者信息

Strunoiu Livia Mihaela, Duţescu Mircea Mihai, Strunoiu Cristian Marian, Alexandru Dragoş Ovidiu, Pîrlog Mihail Cristian, Tica Andrei Adrian

机构信息

Doctoral School, University of Medicine and Pharmacy of Craiova, Romania, Outpatient Psychiatric Unit, Municipal Hospital "Filantropia" Craiova, Romania.

Doctoral School, University of Medicine and Pharmacy of Craiova, Romania, Chronic Hospital of Psychiatry, Dumbrăveni, Romania.

出版信息

Curr Health Sci J. 2021 Apr-Jun;47(2):237-248. doi: 10.12865/CHSJ.47.02.14. Epub 2021 Jun 30.

DOI:10.12865/CHSJ.47.02.14
PMID:34765244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8551897/
Abstract

MATERIAL AND METHOD

We analyzed 362 patients with schizophrenia admitted during 2016 in an acute psychiatric ward and in a chronic psychiatric ward, diagnosed with paranoid or other schizophrenia, according to DSM-IV-TR, which, after remission of the symptoms of the acute episode, they benefited from antipsychotic therapy only in oral formulation. For some of these patients we instituted maintenance therapy with depot formulas. Patients were followed for up to two years.

RESULTS

Comparing the level of adherence to therapy, we found a statistically significant improvement, from 42.96% to 76.30%. Although we estimate that adherence to LAI therapy is over 90%, almost a quarter of patients have given up this type of treatment at some point due to side effects. Carrying out the comparative analysis of the number of hospitalizations per year, from the past and from the follow-up period, as well as of the scores registered at the scales used (PANSS, CGI, GAS, WHOQOL), in dynamics, we demonstrated the appearance of statistically significant changes.

CONCLUSIONS

the administration of antipsychotic therapy through LAI-type depot formulas can improve the therapeutic adherence of the patient with schizophrenia, thus improving the evolution of the disease and the quality of life.

摘要

材料与方法

我们分析了2016年期间入住急性精神科病房和慢性精神科病房的362例精神分裂症患者，这些患者根据《精神疾病诊断与统计手册》第四版修订版（DSM-IV-TR）被诊断为偏执型或其他类型精神分裂症，在急性发作症状缓解后，他们仅接受口服抗精神病药物治疗。对于其中一些患者，我们采用长效制剂进行维持治疗。对患者进行了长达两年的随访。

结果

比较治疗依从性水平，我们发现有统计学意义的改善（从42.96%提高到76.30%）。尽管我们估计长效注射治疗的依从性超过90%，但几乎四分之一的患者在某个时候因副作用而放弃了这种治疗方式。对过去和随访期间每年的住院次数以及所使用量表（阳性和阴性症状量表、临床总体印象量表、大体评定量表、世界卫生组织生活质量量表）记录的分数进行动态比较分析，我们证明出现了有统计学意义的变化。

结论

通过长效注射型制剂给予抗精神病药物治疗可提高精神分裂症患者的治疗依从性，从而改善疾病进展和生活质量

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/2648952c7b17/CHSJ-47-02-237-fig13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/ed09a4b459a8/CHSJ-47-02-237-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/8783bcdd4b8b/CHSJ-47-02-237-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/10f8d713ebf2/CHSJ-47-02-237-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/d30661ecb599/CHSJ-47-02-237-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/fb196fd03a3f/CHSJ-47-02-237-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/5c8a890be1a2/CHSJ-47-02-237-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/f6d8bfae0991/CHSJ-47-02-237-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/82f054e87d4b/CHSJ-47-02-237-fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/b1bd46392b6b/CHSJ-47-02-237-fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/61aff367e79d/CHSJ-47-02-237-fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/6b39cd00c3d2/CHSJ-47-02-237-fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/898d7d75a489/CHSJ-47-02-237-fig12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/2648952c7b17/CHSJ-47-02-237-fig13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/ed09a4b459a8/CHSJ-47-02-237-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/8783bcdd4b8b/CHSJ-47-02-237-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/10f8d713ebf2/CHSJ-47-02-237-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/d30661ecb599/CHSJ-47-02-237-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/fb196fd03a3f/CHSJ-47-02-237-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/5c8a890be1a2/CHSJ-47-02-237-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/f6d8bfae0991/CHSJ-47-02-237-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/82f054e87d4b/CHSJ-47-02-237-fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/b1bd46392b6b/CHSJ-47-02-237-fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/61aff367e79d/CHSJ-47-02-237-fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/6b39cd00c3d2/CHSJ-47-02-237-fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/898d7d75a489/CHSJ-47-02-237-fig12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a49/8551897/2648952c7b17/CHSJ-47-02-237-fig13.jpg

相似文献

1
The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia.换用长效注射用抗精神病药物治疗对精神分裂症患者的影响。
Curr Health Sci J. 2021 Apr-Jun;47(2):237-248. doi: 10.12865/CHSJ.47.02.14. Epub 2021 Jun 30.
2
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].[精神分裂症患者护理环境的成本效益分析：长效注射制剂下非典型抗精神病药物的影响]
Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5.
3
Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.阿立哌唑长效注射剂治疗患者的临床演变：一项初步的、前瞻性、观察性研究。
Int J Psychiatry Clin Pract. 2020 Mar;24(1):10-17. doi: 10.1080/13651501.2019.1711130. Epub 2020 Jan 14.
4
Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study.首发精神分裂症患者口服与长效注射用抗精神病药物的比较：一项为期12周的干预性研究。
Indian J Psychiatry. 2023 Apr;65(4):404-411. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22. Epub 2023 Apr 11.
5
[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].[法国生物精神病学与神经精神药理学协会特别工作组：长效抗精神病药物处方的正式共识]
Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0.
6
[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].[使用长效注射用利培酮的基本原理：法国精神科医生的一项调查]
Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28.
7
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.慢性精神分裂症患者从长效抗精神病药物换用奥氮平的情况
J Clin Psychiatry. 2003 Feb;64(2):119-22. doi: 10.4088/jcp.v64n0203.
8
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.奥氮平长效注射剂治疗急性精神分裂症患者的8周双盲随机安慰剂对照研究
J Clin Psychiatry. 2008 May;69(5):790-9. doi: 10.4088/jcp.v69n0512.
9
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.将稳定期精神分裂症或分裂情感性障碍患者由奥氮平转换为利培酮长效注射剂。
Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.
10
Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.抗精神病药物用于首发精神分裂症 24 个月维持治疗的效果：一项基于社区的“真实世界”研究的证据。
J Clin Psychiatry. 2016 Nov;77(11):e1460-e1466. doi: 10.4088/JCP.15m10047.

引用本文的文献

1
A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia.抗精神病药物对精神分裂症患者生活质量影响的系统评价
Brain Sci. 2023 Nov 10;13(11):1577. doi: 10.3390/brainsci13111577.

本文引用的文献

1
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.首发精神分裂症患者使用阿立哌唑长效注射剂的探索性分析
Front Psychiatry. 2020 Jan 8;10:935. doi: 10.3389/fpsyt.2019.00935. eCollection 2019.
2
Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.优化治疗选择以改善精神分裂症的依从性和结局。
J Clin Psychiatry. 2019 Sep 17;80(5):IN18031AH1C. doi: 10.4088/JCP.IN18031AH1C.
3
The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia.
长效注射用抗精神病药物在以患者为中心的精神分裂症护理中的现代视角。
Neuropsychiatr Dis Treat. 2019 Apr 30;15:1045-1060. doi: 10.2147/NDT.S199048. eCollection 2019.
4
Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life.阿立哌唑长效注射剂（LAI）与帕利哌酮LAI治疗合并精神病和物质使用障碍的1年疗效对比：对临床状态、物质渴望及生活质量的影响
Neuropsychiatr Dis Treat. 2018 Jun 21;14:1645-1656. doi: 10.2147/NDT.S171002. eCollection 2018.
5
Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing.精神分裂症患者的药物依从性：动机访谈中患者过程的定性研究。
BMC Psychiatry. 2018 May 18;18(1):135. doi: 10.1186/s12888-018-1724-9.
6
Revised manual for the Global Assessment of Functioning scale.《全球功能评估量表手册修订版》。
Eur Psychiatry. 2018 Jun;51:16-19. doi: 10.1016/j.eurpsy.2017.12.028. Epub 2018 Mar 3.
7
An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS).对精神分裂症中常用的五种症状评定量表（阳性和阴性症状量表、简明精神病评定量表、阴性症状评定量表、NSA - 16、临床总体印象 - 精神分裂症）的评估及与新量表（临床衰退评估量表、简明阴性症状量表）的比较
J Addict Res Ther. 2017;8(3). doi: 10.4172/2155-6105.1000324. Epub 2017 May 11.
8
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.精神分裂症或双相情感障碍患者中长效注射用与口服抗精神病药物的用药依从性及停药情况
J Med Econ. 2018 Feb;21(2):127-134. doi: 10.1080/13696998.2017.1379412. Epub 2017 Sep 29.
9
Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study).在现实临床环境中接受长效注射利培酮治疗的精神分裂症谱系患者：缓解期与稳定期、未缓解患者的功能恢复情况（EVeREST前瞻性观察队列研究）
BMC Psychiatry. 2016 Jan 15;16:8. doi: 10.1186/s12888-016-0712-1.
10
Clinical pharmacology of atypical antipsychotics: an update.非典型抗精神病药物的临床药理学：最新进展
EXCLI J. 2014 Oct 13;13:1163-91. eCollection 2014.